Zoetis Inc. $ZTS Shares Sold by Novare Capital Management LLC

Novare Capital Management LLC lowered its stake in shares of Zoetis Inc. (NYSE:ZTS) by 56.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 38,614 shares of the company’s stock after selling 49,119 shares during the period. Novare Capital Management LLC’s holdings in Zoetis were worth $4,858,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. RFG Advisory LLC boosted its stake in Zoetis by 4.9% during the fourth quarter. RFG Advisory LLC now owns 1,708 shares of the company’s stock worth $215,000 after buying an additional 80 shares during the last quarter. YANKCOM Partnership lifted its stake in shares of Zoetis by 3.5% in the 4th quarter. YANKCOM Partnership now owns 2,402 shares of the company’s stock valued at $302,000 after purchasing an additional 81 shares during the last quarter. Evergreen Capital Management LLC lifted its stake in shares of Zoetis by 3.3% in the 3rd quarter. Evergreen Capital Management LLC now owns 2,696 shares of the company’s stock valued at $394,000 after purchasing an additional 85 shares during the last quarter. Beese Fulmer Investment Management Inc. lifted its stake in shares of Zoetis by 2.4% in the 3rd quarter. Beese Fulmer Investment Management Inc. now owns 3,672 shares of the company’s stock valued at $537,000 after purchasing an additional 85 shares during the last quarter. Finally, Quest 10 Wealth Builders Inc. lifted its stake in shares of Zoetis by 4.7% in the 4th quarter. Quest 10 Wealth Builders Inc. now owns 1,904 shares of the company’s stock valued at $240,000 after purchasing an additional 86 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Analyst Ratings Changes

ZTS has been the topic of several recent analyst reports. JPMorgan Chase & Co. decreased their price target on Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Morgan Stanley reaffirmed an “overweight” rating and issued a $115.00 price target on shares of Zoetis in a research note on Friday. Weiss Ratings lowered Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, March 27th. Wall Street Zen lowered Zoetis from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Finally, BTIG Research reaffirmed a “buy” rating and issued a $160.00 price target on shares of Zoetis in a research note on Thursday, February 26th. Seven equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $137.50.

Insiders Place Their Bets

In related news, Director Frank A. Damelio purchased 6,650 shares of the business’s stock in a transaction on Wednesday, May 13th. The shares were bought at an average price of $75.39 per share, for a total transaction of $501,343.50. Following the acquisition, the director directly owned 21,458 shares in the company, valued at $1,617,718.62. This trade represents a 44.91% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Michael B. Mccallister purchased 3,000 shares of the business’s stock in a transaction on Monday, May 11th. The shares were bought at an average price of $77.76 per share, for a total transaction of $233,280.00. Following the acquisition, the director owned 24,524 shares in the company, valued at $1,906,986.24. This trade represents a 13.94% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 11,650 shares of company stock worth $886,384 in the last quarter. 0.22% of the stock is owned by company insiders.

Zoetis Price Performance

Shares of NYSE ZTS opened at $74.11 on Friday. The stock’s 50-day moving average is $112.28 and its two-hundred day moving average is $120.94. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91. Zoetis Inc. has a 1-year low of $72.38 and a 1-year high of $172.23. The company has a market cap of $31.07 billion, a price-to-earnings ratio of 12.29, a price-to-earnings-growth ratio of 1.23 and a beta of 0.87.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The company had revenue of $2.26 billion for the quarter, compared to analysts’ expectations of $2.30 billion. During the same quarter last year, the company earned $1.48 EPS. Zoetis’s revenue for the quarter was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Analysts forecast that Zoetis Inc. will post 6.89 EPS for the current fiscal year.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.